RICCIARDI, GIUSEPPINA ROSARIA
 Distribuzione geografica
Continente #
NA - Nord America 685
EU - Europa 602
AS - Asia 128
OC - Oceania 1
Totale 1.416
Nazione #
US - Stati Uniti d'America 685
IE - Irlanda 175
SE - Svezia 169
CN - Cina 102
IT - Italia 80
PL - Polonia 28
FI - Finlandia 26
FR - Francia 23
DE - Germania 20
GB - Regno Unito 20
UA - Ucraina 20
BE - Belgio 19
IN - India 18
AT - Austria 17
VN - Vietnam 5
CZ - Repubblica Ceca 3
IR - Iran 2
AU - Australia 1
JP - Giappone 1
RO - Romania 1
RU - Federazione Russa 1
Totale 1.416
Città #
Dublin 174
Chandler 159
Nyköping 86
Ashburn 76
Jacksonville 54
Ann Arbor 52
Beijing 48
New York 28
Warsaw 28
Messina 26
Princeton 25
Medford 24
Cambridge 23
Brussels 19
Dearborn 18
Des Moines 18
Vienna 17
Pune 15
Boardman 13
Woodbridge 12
Jinan 9
Lancaster 8
Milan 8
Nanjing 8
San Mateo 8
Tianjin 6
Wilmington 6
Dong Ket 5
Giardini-Naxos 4
Hangzhou 4
Hebei 4
Leawood 4
Bremen 3
Fuzhou 3
Jiaxing 3
Nanchang 3
Ningbo 3
Olomouc 3
Shenyang 3
Trepuzzi 3
Catania 2
Grammichele 2
Hyderabad 2
Lissone 2
Monmouth Junction 2
Ozzano dell'Emilia 2
Taizhou 2
Washington 2
Zhengzhou 2
Acireale 1
Ardabil 1
Cannock 1
Changsha 1
Fort Washington 1
Guangzhou 1
Haikou 1
Helsinki 1
Hendon 1
Houston 1
Iasi 1
Los Angeles 1
Mountain View 1
Mountmellick 1
Norwalk 1
Philadelphia 1
Rüsselsheim 1
Simi Valley 1
Sydney 1
Tehran 1
Wenzhou 1
Totale 1.052
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 101
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 86
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 74
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 74
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 74
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 73
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 71
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 64
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 60
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 58
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 56
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 54
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 54
null 52
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 51
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 49
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 49
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 47
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 44
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 42
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 42
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 41
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 41
Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. 36
null 22
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals 18
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 13
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes 3
Totale 1.449
Categoria #
all - tutte 5.063
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.063


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20196 0 0 0 0 0 0 0 0 0 0 0 6
2019/2020152 12 2 4 2 0 22 18 17 6 36 26 7
2020/2021200 16 0 33 24 18 18 13 7 11 22 25 13
2021/2022189 3 21 5 5 3 4 10 6 3 47 23 59
2022/2023551 39 61 21 45 47 63 9 33 218 1 11 3
2023/2024197 7 21 11 12 9 70 57 2 2 3 2 1
Totale 1.449